Health Care Related Organization
Pfizer and Valneva Report Strong Immune Responses from Second Lyme Disease Vaccine Booster
Lyme disease, vaccine, Pfizer, Valneva, VLA15, booster, immune response, Phase 2 trials, FDA submission
FDA Authorizes Novavax’s Updated COVID-19 Vaccine for Emergency Use
Novavax COVID-19 Vaccine, FDA Authorization, Emergency Use, Protein-Based Vaccine, JN.1 Variant
Abbott MitraClip Demonstrates Significant Benefits in Treating Functional, Leaky Heart Valves
MitraClip, Abbott, Heart Valve Disease, Secondary Mitral Regurgitation, Transcatheter Mitral Valve Repair
Roche’s Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Phase II Trial
Roche, fenebrutinib, relapsing multiple sclerosis, BTK inhibitor, Phase II trial, FENopta study
Pfizer and Valneva Announce Positive Phase 2 Results for Lyme Disease Vaccine Candidate VLA15
Lyme disease, VLA15, Pfizer, Valneva, vaccine development, tick-borne diseases
Sanofi’s Tolebrutinib Shows Mixed Results in Phase 3 MS Trials, Plans for FDA Filing Remain
Tolebrutinib, Sanofi, Multiple Sclerosis, Phase 3 Trials, FDA Filing
Novavax’s Updated COVID-19 Vaccine Receives FDA Emergency Use Authorization
Novavax, COVID-19 vaccine, FDA, Emergency Use Authorization, protein-based vaccine, JN.1 variant
Women Breaking Barriers in Drug Development: Celebrating Leadership and Innovation
Women in drug development, gender equity, STEM, pharmaceutical industry, leadership, innovation
Sanofi’s Tolebrutinib Shows Mixed Results in Multiple Sclerosis Trials
Sanofi, Tolebrutinib, Multiple Sclerosis, BTK Inhibitor, Clinical Trials
QIAGEN and AstraZeneca Enhance Partnership to Develop Companion Diagnostics for Chronic Diseases
QIAGEN, AstraZeneca, companion diagnostics, chronic diseases, precision medicine, QIAstat-Dx, genotyping assay